혈액제재 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Blood Products Market size is expected to reach USD 79.97 Billion in 2034 from USD 38.50 Billion (2025) growing at a CAGR of 8.46% during 2026-2034.

The Blood Products market is experiencing robust growth, driven by the increasing demand for blood transfusions and the rising prevalence of chronic diseases that necessitate blood product utilization. As healthcare systems worldwide strive to improve patient outcomes, the importance of safe and effective blood products cannot be overstated. This market encompasses a wide range of products, including whole blood, red blood cells, plasma, and platelets, all of which play critical roles in medical treatments and surgical procedures. The growing aging population and the surge in trauma cases are further propelling the demand for blood products, highlighting the need for efficient blood collection, processing, and distribution systems.

Technological advancements are significantly enhancing the capabilities of the Blood Products market, with innovations in blood processing and storage techniques improving product safety and efficacy. The development of automated blood collection systems and advanced testing methods is streamlining operations and reducing the risk of contamination. Additionally, the integration of data analytics and artificial intelligence in blood management systems is optimizing inventory control and ensuring that blood products are available when and where they are needed most. As the market continues to evolve, companies that invest in cutting-edge technologies and prioritize quality assurance will likely gain a competitive advantage.

Moreover, the Blood Products market is increasingly influenced by regulatory frameworks and public health initiatives aimed at ensuring the safety and availability of blood supplies. Governments and health organizations are implementing stringent regulations to enhance blood safety and promote voluntary blood donation campaigns. This focus on safety and accessibility is driving investment in blood donation infrastructure and awareness programs, creating opportunities for growth in the market. As the demand for blood products continues to rise, companies that align their operations with regulatory standards and engage in community outreach will be well-positioned to succeed in this vital sector.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Albumin
• Immunoglobulin
• Clotting Factor
• Others

By Application

• Bleeding Wound
• Immunodeficiency
• HBV
• Tetanus
• Rabies
• Hemophilia
• Others

COMPANIES PROFILED

• CSL, BPL, Mitsubishi Tanabe Pharma Corporation, Takeda, Octapharma AG, Baxter, Grifols, Kedrion SpA, Hualan Bio

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BLOOD PRODUCTS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Albumin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunoglobulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Clotting Factor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BLOOD PRODUCTS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Bleeding Wound Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immunodeficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. HBV Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Tetanus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Rabies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Hemophilia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BLOOD PRODUCTS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BLOOD PRODUCTS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 CSL
  • 8.2.2 BPL
  • 8.2.3 Mitsubishi Tanabe Pharma Corporation
  • 8.2.4 Takeda
  • 8.2.5 Octapharma AG
  • 8.2.6 Baxter
  • 8.2.7 Grifols
  • 8.2.8 Kedrion SpA
  • 8.2.9 Hualan Bio